Hims & Hers Health Reports Better-Than-Expected Q3 Results: Details

Benzinga
2024-11-05

Hims & Hers Health, Inc. (NYSE:HIMS) reported its third-quarter results after Monday's closing bell. Here's a look at the details from the report.  

The Details: Hims & Hers Health reported quarterly earnings of 32 cents per share, which beat the analyst consensus estimate of 4 cents. Quarterly revenue came in at $401.6 million, which beat the analyst consensus estimate of $382.2 million and is an increase over sales of $226.7 million from the same period last year.

  • Subscribers reached two million in the quarter, up 44% year-over-year.
  • Gross margin was 79% for the third quarter of 2024 compared to 83% for the third quarter of 2023.
  • Net income was $75.6 million for the third quarter of 2024, which included a $60.8 million tax benefit related to the release of a tax valuation allowance, partially offset by current period tax expense. This compared to a net loss of $7.6 million for the third quarter of 2023.

Read Next: Trump Media Stock Volatile On Election Eve As Polls, Betting Markets Predict Tight White House Race

“Improving momentum in both the Hims and Hers brands delivered another strong quarter of growth and profitability,” said Andrew Dudum, co-founder and CEO. “Our execution against a strategy that brings customers convenient, transparent, and affordable access to care designed specifically for them is allowing us to reach millions of individuals across the country.”

Outlook: Hims & Hers sees fourth-quarter revenue of between $465 million and $470 million and raised its fiscal 2024 revenue guidance to a range of $1.46 billion to $1.465 billion versus the $1.396 billion estimate.

HIMS Price Action: According to Benzinga Pro, Hims & Hers Health shares are up 7.90% after-hours at $22.40 at the time of publication Monday.

Read Also: 

  • Alibaba Layoffs Hit Metaverse Division: Will The Chinese E-Commerce Giant Double-Down On AI? 

Photo: Courtesy of Hims & Hers Health, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10